Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

Mar 21 2018

• By Mandy Jackson

US dollars

Related Content

Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval

Sep 04 2017

Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic

Mar 06 2018

Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product

Mar 16 2018

Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Jan 27 2012

VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups

Dec 23 2016

Related Companies

Novartis AG

Gilead Sciences, Inc.

Kite Pharma, Inc.

Adaptimmune Therapeutics plc

Bluebird Bio

Bristol Myers Squibb Company

Bristol Myers Squibb Company

GSK plc

Amgen, Inc.

Micromet, Inc.

Additional Topics

Financing ImmunoOncology StartUps and SMEs Companies Business Strategies Commercial Cancer BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.